PURPOSE OF REVIEW: Artemisinin-based combination therapies (ACTs) have been deployed globally with remarkable success for more than 10 years without having lost their malaria treatment efficacy. However, recent reports from the Thai-Cambodian border reveal evidence of emerging resistance to artemisinins. The latest published clinical and molecular findings are summarized herein. RECENT FINDINGS: Clinical studies have identified delayed parasite clearance time as the most robust marker of artemisinin resistance. Resistance has only been documented from South-east Asia and has been observed in isolates that show no significant decrease in drug susceptibility in vitro. Genetic investigations have yet to uncover robust molecular markers. In-vitro studies have identified parasite quiescence or dormancy mechanisms that protect early 'ring-stage' intra-erythrocytic parasites against short-term artemisinin exposure. This might be achieved by reducing the rate of hemoglobin degradation, important for artemisinin bioactivation. SUMMARY: Should ACTs fail, no suitable alternatives exist as first-line treatments of P. falciparum malaria. Intensified efforts are essential to monitor the spread of resistance, define therapeutic and operational strategies to counter its impact, and understand its molecular basis. Success in these areas is critical to ensuring that recent gains in reducing the burden of malaria are not lost.
PURPOSE OF REVIEW: Artemisinin-based combination therapies (ACTs) have been deployed globally with remarkable success for more than 10 years without having lost their malaria treatment efficacy. However, recent reports from the Thai-Cambodian border reveal evidence of emerging resistance to artemisinins. The latest published clinical and molecular findings are summarized herein. RECENT FINDINGS: Clinical studies have identified delayed parasite clearance time as the most robust marker of artemisinin resistance. Resistance has only been documented from South-east Asia and has been observed in isolates that show no significant decrease in drug susceptibility in vitro. Genetic investigations have yet to uncover robust molecular markers. In-vitro studies have identified parasite quiescence or dormancy mechanisms that protect early 'ring-stage' intra-erythrocytic parasites against short-term artemisinin exposure. This might be achieved by reducing the rate of hemoglobin degradation, important for artemisinin bioactivation. SUMMARY: Should ACTs fail, no suitable alternatives exist as first-line treatments of P. falciparum malaria. Intensified efforts are essential to monitor the spread of resistance, define therapeutic and operational strategies to counter its impact, and understand its molecular basis. Success in these areas is critical to ensuring that recent gains in reducing the burden of malaria are not lost.
Authors: Harald Noedl; Youry Se; Kurt Schaecher; Bryan L Smith; Duong Socheat; Mark M Fukuda Journal: N Engl J Med Date: 2008-12-08 Impact factor: 91.245
Authors: Nanhua Chen; Marina Chavchich; Jennifer M Peters; Dennis E Kyle; Michelle L Gatton; Qin Cheng Journal: Antimicrob Agents Chemother Date: 2010-04-26 Impact factor: 5.191
Authors: Maria Isabel Veiga; Pedro Eduardo Ferreira; Louise Jörnhagen; Maja Malmberg; Aminatou Kone; Berit Aydin Schmidt; Max Petzold; Anders Björkman; Francois Nosten; Jose Pedro Gil Journal: PLoS One Date: 2011-05-25 Impact factor: 3.240
Authors: Paul Hunt; Ana Afonso; Alison Creasey; Richard Culleton; Amar Bir Singh Sidhu; John Logan; Stephanie G Valderramos; Iain McNae; Sandra Cheesman; Virgilio do Rosario; Richard Carter; David A Fidock; Pedro Cravo Journal: Mol Microbiol Date: 2007-07 Impact factor: 3.501
Authors: David M Rubush; Michelle A Morges; Barbara J Rose; Douglas H Thamm; Tomislav Rovis Journal: J Am Chem Soc Date: 2012-08-07 Impact factor: 15.419
Authors: Nectarios Klonis; Stanley C Xie; James M McCaw; Maria P Crespo-Ortiz; Sophie G Zaloumis; Julie A Simpson; Leann Tilley Journal: Proc Natl Acad Sci U S A Date: 2013-02-19 Impact factor: 11.205
Authors: Mahoutin H Noukpo; Georgia B Damien; Emmanuel Elanga-N'Dille; André B Sagna; Papa M Drame; Evelyne Chaffa; Olayidé Boussari; Vincent Corbel; Martin Akogbéto; Franck Remoue Journal: Am J Trop Med Hyg Date: 2016-10-24 Impact factor: 2.345
Authors: Kirsten K Hanson; Ana S Ressurreição; Kathrin Buchholz; Miguel Prudêncio; Jonathan D Herman-Ornelas; Maria Rebelo; Wandy L Beatty; Dyann F Wirth; Thomas Hänscheid; Rui Moreira; Matthias Marti; Maria M Mota Journal: Proc Natl Acad Sci U S A Date: 2013-07-08 Impact factor: 11.205
Authors: Charlotte A Lanteri; Suwanna Chaorattanakawee; Chanthap Lon; David L Saunders; Wiriya Rutvisuttinunt; Kritsanai Yingyuen; Ian Bathurst; Xavier C Ding; Stuart D Tyner Journal: Antimicrob Agents Chemother Date: 2014-07-21 Impact factor: 5.191
Authors: Marianne de Villiers; Cristiano Macuamule; Christina Spry; Yoo-Min Hyun; Erick Strauss; Kevin J Saliba Journal: ACS Med Chem Lett Date: 2013-06-17 Impact factor: 4.345
Authors: Alexander M Jacobine; Jennifer R Mazzone; Rachel D Slack; Abhai K Tripathi; David J Sullivan; Gary H Posner Journal: J Med Chem Date: 2012-08-27 Impact factor: 7.446